Abstract
Depressive disorders have, for a sizeable extent, proven resilient to pharmacotherapy. Established drugs such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) often provide inadequate symptom relief and sometimes fail altogether. Recently, interest in antidepressant effects of scopolamine, a non-selective muscarinic acetylcholine receptor (mAChR) antagonist, has arisen. Initial evidence suggests that scopolamine provides relatively rapid and long-lasting symptom alleviation for unipolar and bipolar depressed patients. At the same time, side effects of medical dosages appear mild and transient in nature. The aim of the present review is to tentatively discuss the antidepressant potential of scopolamine and to outline putative neurobiological pathways. Clearly, mAChR antagonism provides an intriguing novel therapeutical approach for treating depressive disorders.
Keywords: Acetylcholine, antidepressants, depression, muscarinic receptors, monoamines, scopolamine.
CNS & Neurological Disorders - Drug Targets
Title:Scopolamine and Depression: A Role for Muscarinic Antagonism?
Volume: 13 Issue: 4
Author(s): Helge Hasselmann
Affiliation:
Keywords: Acetylcholine, antidepressants, depression, muscarinic receptors, monoamines, scopolamine.
Abstract: Depressive disorders have, for a sizeable extent, proven resilient to pharmacotherapy. Established drugs such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) often provide inadequate symptom relief and sometimes fail altogether. Recently, interest in antidepressant effects of scopolamine, a non-selective muscarinic acetylcholine receptor (mAChR) antagonist, has arisen. Initial evidence suggests that scopolamine provides relatively rapid and long-lasting symptom alleviation for unipolar and bipolar depressed patients. At the same time, side effects of medical dosages appear mild and transient in nature. The aim of the present review is to tentatively discuss the antidepressant potential of scopolamine and to outline putative neurobiological pathways. Clearly, mAChR antagonism provides an intriguing novel therapeutical approach for treating depressive disorders.
Export Options
About this article
Cite this article as:
Hasselmann Helge, Scopolamine and Depression: A Role for Muscarinic Antagonism?, CNS & Neurological Disorders - Drug Targets 2014; 13 (4) . https://dx.doi.org/10.2174/1871527313666140618105710
DOI https://dx.doi.org/10.2174/1871527313666140618105710 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoamine Oxidases: to Inhibit or Not to Inhibit
Mini-Reviews in Medicinal Chemistry The Importance of Alkynyl Chain Presence for the Activity of Adenine Nucleosides/Nucleotides on Purinergic Receptors
Current Medicinal Chemistry Conventional Chemotherapy and Emerging Targeted Therapy for Advanced Adrenocortical Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Insulin and Endothelial Function: Physiological Environment Defines Effect on Atherosclerotic Risk
Current Diabetes Reviews Vaccination Against High Blood Pressure
Current Pharmaceutical Design Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development
Current Medicinal Chemistry Novel Biomass Derived from Grape Pomace Waste as an Efficient Nanocatalyst for the Synthesis of Dibenzoxanthene, Tetraketone, bis(indolyl)alkane and Chromene Derivatives and their Antimicrobial Evaluation
Current Organic Synthesis Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets The Oxygen Therapy
Current Medicinal Chemistry ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Pharmacologic Agents for the Treatment of Vasodilatory Shock
Current Pharmaceutical Design Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Structure-Activity Relationships of KATP Channel Openers
Current Topics in Medicinal Chemistry Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update
Current Pediatric Reviews